Your browser is no longer supported. Please, upgrade your browser.
HOTH Hoth Therapeutics, Inc. daily Stock Chart
Hoth Therapeutics, Inc.
Index- P/E- EPS (ttm)-0.31 Insider Own34.70% Shs Outstand10.48M Perf Week-7.66%
Market Cap45.48M Forward P/E- EPS next Y-0.38 Insider Trans0.00% Shs Float4.42M Perf Month8.77%
Income-3.30M PEG- EPS next Q-0.10 Inst Own0.10% Short Float0.55% Perf Quarter-22.56%
Sales- P/S- EPS this Y-131.90% Inst Trans- Short Ratio1.76 Perf Half Y-14.06%
Book/sh0.43 P/B10.19 EPS next Y11.60% ROA- Target Price10.00 Perf Year-
Cash/sh0.31 P/C14.21 EPS next 5Y- ROE- 52W Range3.26 - 13.88 Perf YTD-49.12%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-68.73% Beta-
Dividend %- Quick Ratio163.30 Sales past 5Y- Gross Margin- 52W Low33.13% ATR0.42
Employees2 Current Ratio- Sales Q/Q- Oper. Margin- RSI (14)49.73 Volatility5.73% 10.34%
OptionableNo Debt/Eq0.00 EPS Q/Q- Profit Margin- Rel Volume0.43 Prev Close4.50
ShortableYes LT Debt/Eq0.00 EarningsNov 13 Payout- Avg Volume13.88K Price4.34
Recom2.00 SMA202.36% SMA50-2.10% SMA200-18.81% Volume5,922 Change-3.56%
Oct-15-19Initiated The Benchmark Company Speculative Buy $10
Nov-14-19 08:00AM  Hoth Therapeutics Initiates Preclinical Study Including Topical Form of Aprepitant for Dermatological Treatment Relating to Side Effects of Cancer Medication PR Newswire
Nov-11-19 01:42PM  We're Not Very Worried About Hoth Therapeutics's (NASDAQ:HOTH) Cash Burn Rate Simply Wall St.
Nov-06-19 08:00AM  Hoth Therapeutics Initiates Confirmatory Study for Lupus Treatment PR Newswire
Oct-16-19 11:53AM  Four Innovators Targeting Multi-Billion-Dollar Market Opportunities in: E-Commerce, Healthcare Augmented Reality, and Cannabis GlobeNewswire
Oct-15-19 08:00AM  Hoth Therapeutics to Present at the Dawson James 5th Annual Small Cap Growth Conference PR Newswire
Oct-14-19 08:00AM  Hoth Therapeutics Makes Donation to National Eczema Association in Sponsorship of "National Eczema Awareness Month" PR Newswire
Oct-08-19 08:30AM  Hoth Therapeutics Successfully Completes Phase I of In-Life Dose Escalation Study for Treating Eczema PR Newswire
Sep-25-19 12:32PM  Wall Street Reporter presents: NEXT SUPER STOCK - Live! Investor Conference September 26, 2019 GlobeNewswire
10:09AM  Emerging Markets Report: Looking Beyond Skin Deep GlobeNewswire
Sep-24-19 08:00AM  Hoth Therapeutics, Inc. to Present at Diamond Equity Research Emerging Growth Invitational PR Newswire
Sep-18-19 10:51AM  New Ideas for Billion Dollar Markets: Emerging Leaders in Cannabis, Augmented Reality, and Healthcare GlobeNewswire -6.54%
Sep-16-19 02:41PM  Next Super Stock conference presenters: CYDY, MDCL, HOTH, NEXCF delivering results, and positioned for transformational growth in coming months GlobeNewswire
09:30AM  Diamond Equity Research Initiates Coverage on Hoth Therapeutics, Inc. (NASDAQ: HOTH) ACCESSWIRE
Sep-06-19 08:00AM  Hoth Therapeutics to Present at the H.C. Wainwright 21st Annual Global Investment Conference and RESI 2019 Boston Conference PR Newswire
Sep-04-19 08:00AM  Hoth Therapeutics, Inc. Issues Letter to Shareholders PR Newswire
Aug-21-19 08:00AM  Hoth Therapeutics and Zylö Therapeutics Finalize Agreement PR Newswire
Aug-01-19 02:25PM  What Kind Of Shareholders Own Hoth Therapeutics, Inc. (NASDAQ:HOTH)? Simply Wall St.
Jul-22-19 08:00AM  Hoth Therapeutics, Inc. Announces Positive Results from Pilot Study of BioLexa on Diabetic Skin Ulcers PR Newswire -5.56%
Jul-15-19 08:00AM  Hoth Therapeutics, Inc. Expands Working Relationship with the George Washington University and Enters Exclusive License Option Agreement PR Newswire
Jun-27-19 08:00AM  Hoth Therapeutics, Inc. Enters into Sponsored Research Agreement with the George Washington University PR Newswire +7.14%
Jun-13-19 08:00AM  Hoth Therapeutics to Present to Investors at the Union League of Philadelphia PR Newswire +5.84%
Jun-10-19 08:00AM  Hoth Therapeutics to Begin Production of BioLexa Therapeutic for Upcoming Toxicology and Clinical Trials PR Newswire +5.56%
Jun-06-19 08:00AM  Hoth Therapeutics Forms Wholly Owned Australian Subsidiary, in Preparation of Upcoming Clinical Trials for Atopic Dermatitis Solution PR Newswire
May-29-19 08:00AM  Hoth Therapeutics to Present at the 9th Annual LD Micro Invitational Investor Conference on June 4th, 2019 PR Newswire
May-14-19 08:00AM  Hoth Therapeutics Signs Term Sheet with Zylö Therapeutics to Acquire a License and Jointly Develop a Product to Treat Lupus PR Newswire +10.81%
Apr-30-19 08:00AM  Hoth Therapeutics, Inc. to Present at the ThinkEquity Conference PR Newswire
Apr-18-19 08:00AM  Hoth Therapeutics, Inc. to Ring NASDAQ Closing Bell on April 22, 2019 PR Newswire
Apr-08-19 08:00AM  Hoth Therapeutics, Inc. Announces the Addition of Dr. Lawrence A. Schachner, M.D. and Dr. Vincent C.O. Njar, Ph.D. to the Company's Scientific Advisory Board PR Newswire
Mar-19-19 08:00AM  Hoth Therapeutics, Inc. Announces the Addition of Dr. Stefanie Johns, Ph.D. to the Company's Scientific Advisory Board PR Newswire
Mar-13-19 08:00AM  Hoth Therapeutics Enters into Commercial Licensing Agreement with University of Maryland, Baltimore and Isoprene Pharmaceuticals Inc. PR Newswire -5.43%
Mar-11-19 08:00AM  Hoth Therapeutics Announces Dr. Jonathan Zippin as Senior Scientific Advisor PR Newswire
Mar-04-19 08:00AM  Hoth Therapeutics, Inc. to Begin Pilot Study at Massachusetts General Hospital Vaccine and Immunotherapy Center PR Newswire
Feb-25-19 08:00AM  Hoth Therapeutics Inc. Announces the Addition of Dr. Adam Friedman, M.D. to the Company's Scientific Advisory Board GlobeNewswire -6.39%
Feb-20-19 05:15PM  Hoth Therapeutics Inc. Announces Closing of Initial Public Offering GlobeNewswire +11.90%
Feb-15-19 08:00AM  Hoth Therapeutics Inc. Announces Pricing of Initial Public Offering and Trading on the Nasdaq Capital Market Under the Ticker Symbol HOTH GlobeNewswire
Hoth Therapeutics, Inc., a biopharmaceutical company, focuses on developing targeted therapeutics for eczema, dermatological and chronic wound disorders, psoriasis, and acne. It intends to use the BioLexa Platform to develop 2 topical cream products that treat eczema and reduces post-procedure infections for patients undergoing aesthetic dermatology procedures. The company has a sponsored research agreement with the George Washington University to counter the dermatological related side-effects of Erlotinib therapy in cancer patients. The company was incorporated in 2017 and is headquartered in New York, New York.